Scholarlink

<p>In metastatic clear-cell renal cell carcinoma (mccRCC), choosing between immuno-oncology (IO) combinations and IO plus anti-VEGF therapies is uncertain. The BIONIKK trial revealed that ipilimumab plus nivolumab (Ipi/Nivo) achieved a 70% objective response rate in angiogenic cluster1/2 versus 41% in cluster4/5, which featured T-effector/cell-cycle signatures (<i>p</i> = 0.048). Complete responses were exclusively observed in cluster1/2 (<i>p</i> = 0.012), with longer progression-free survival (<i>p</i> = 0.014). Ipi/Nivo may particularly benefit angiogenic mccRCC, supporting molecular subtype-based treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月8日

查看全文
  • Xiaofan Lu,
  • Yann-Alexandre Vano,
  • Xiaoping Su,
  • Virginie Verkarre,
  • Cheng-Ming Sun,
  • Wenxuan Cheng,
  • Li Xu,
  • Fangrong Yan,
  • Salma Kotti,
  • Wolf Herman Fridman,
  • Catherine Sautes-Fridman,
  • Stéphane Oudard,
  • Gabriel G. Malouf

摘要

In metastatic clear-cell renal cell carcinoma (mccRCC), choosing between immuno-oncology (IO) combinations and IO plus anti-VEGF therapies is uncertain. The BIONIKK trial revealed that ipilimumab plus nivolumab (Ipi/Nivo) achieved a 70% objective response rate in angiogenic cluster1/2 versus 41% in cluster4/5, which featured T-effector/cell-cycle signatures (p = 0.048). Complete responses were exclusively observed in cluster1/2 (p = 0.012), with longer progression-free survival (p = 0.014). Ipi/Nivo may particularly benefit angiogenic mccRCC, supporting molecular subtype-based treatment strategies.